Last updated: 2026-09-20 15:46:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Profound Medical Corp. (PROF) operates in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS sector and is listed on NASDAQ. The stock is currently priced at $5,88, with a market capitalisation of $214,13M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $4,17 to $8,95. This page covers its latest market performance, valuation, price trends and company information.
$214,13M | |
$5,85 | |
$28,97 | |
$3,10 | |
$5,89 | |
98,90K | |
108,24K | |
-- | |
$8,95 | |
$4,17 | |
-- | |
-- |
Profound Medical Corp. (PROF) last closed at $5,89 as of 2026-09-18 23:31:00, unchanged from the previous close of $5,89.
During the latest regular trading session, PROF traded between $3,10 and $28,97, with a volume of 98,90K shares. The closing price was near the lower end and near the middle of its 52-week range.
Over the past seven days, Profound Medical Corp. (PROF) moved from $5,96 to $5,88, representing a decline of 1,31% ($0,08).
The stock traded between $5,50 and $6,80 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 152,13 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 35,9%
PROF is currently trading at $5,88, placing it 35,9% of the way from its 52-week low of $4,17 to its 52-week high of $8,95. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.
| Industry | SURGICAL & MEDICAL INSTRUMENTS & APPARATUS |
| Employees | 162 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Profound Medical Corp. (PROF) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.